Clinical TrialJul 7, 2026, 07:31 AM
Cytokinetics to Present Positive ACACIA-HCM Phase 3 Results at ESC Congress
AI Summary
Cytokinetics announced that three Late Breaking Science abstracts, including primary results from the ACACIA-HCM Phase 3 clinical trial of aficamten in non-obstructive hypertrophic cardiomyopathy (HCM), have been accepted for presentation at the European Society of Cardiology (ESC) Congress. The Hot Line presentation of the positive topline results is scheduled for August 28, 2026. The company will also host an investor event to discuss these results.
Key Highlights
- Cytokinetics to present primary results from ACACIA-HCM Phase 3 trial at ESC Congress.
- Hot Line presentation of aficamten results for non-obstructive HCM on August 28, 2026.
- Two additional Late-Breaking Science presentations on August 29, 2026.
- Presentations will be held at the European Society of Cardiology (ESC) Congress in Munich.
- Company will host an in-person and virtual investor event to discuss the results.
- Aficamten (MYQORZO) is already approved for obstructive hypertrophic cardiomyopathy.
Price Impact
More from CYTK